Advertisement

Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2

Published:November 02, 2022DOI:https://doi.org/10.1016/j.braindev.2022.10.006

      Abstract

      Backgrounds

      The efficacy of nusinersen and its evaluation in patients with spinal muscular atrophy (SMA) has been established in clinical trials only for pediatric patients, not for adolescent and adult patients who developed SMA in infancy or early childhood. We report a long-term follow-up in adolescent and adult patients with SMA types 1 and 2.

      Methods

      Nusinersen-treated patients with SMA types 1 and 2 between 2017 and 2022 were retrospectively reviewed. We compared baseline motor function tests with those after the final treatment. Physical and occupational therapists performed Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND), Hammersmith Functional Motor Scale-Expanded (HFMSE), and Revised Upper Limb Module (RULM). The Landau and Galant reflexes were not performed in CHOP-INTEND. Meaningful improvement was defined as CHOP-INTEND, 4; HFSME, 3; and RULM, 2.

      Results

      Seven patients with SMA (type 1, 1; type 2, 6) with a median age of 23 (range, 12–40) years were treated with nusinersen for 3.55 (1.78–4.53) years. Improvement was detected in CHOP-INTEND (pre, 5 [0–31]; post, 21 [0–39]; difference, 5 [0–26]; p = 0.100) without significance, although not in HFMSE (pre, 0 [0–3]; post, 0 [0–5]; difference, 0 [0–2]; p = 0.346) and RULM (pre, 1 [0–20]; post, 3 [0–21]; difference, 1 [0–2]; p = 0.089). Owing to prolonged treatment intervals with the COVID-19 pandemic, RULM worsened in two patients.

      Conclusion

      Nusinersen was effective in long-term follow-up. Only CHOP-INTEND showed meaningful improvement. The interval between doses of nusinersen should not be prolonged even with the COVID-19 pandemic.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Brain and Development
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lefebvre S.
        • Bürglen L.
        • Reboullet S.
        • Clermont O.
        • Burlet P.
        • Viollet L.
        • et al.
        Identification and characterization of a spinal muscular atrophy-determining gene.
        Cell. 1995; 80: 155-165
        • Mercuri E.
        • Finkel R.S.
        • Muntoni F.
        • Wirth B.
        • Montes J.
        • Main M.
        • et al.
        Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care.
        Neuromuscul Disord. 2018; 28: 103-115
        • Finkel R.S.
        • Mercuri E.
        • Darras B.T.
        • Connolly A.M.
        • Kuntz N.L.
        • Kirschner J.
        • et al.
        Nusinersen versus sham control in infantile-onset spinal muscular atrophy.
        N Engl J Med. 2017; 377: 1723-1732
        • Mercuri E.
        • Darras B.T.
        • Chiriboga C.A.
        • Day J.W.
        • Campbell C.
        • Connolly A.M.
        • et al.
        Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
        N Engl J Med. 2018; 378: 625-635
        • Hagenacker T.
        • Wurster C.D.
        • Günther R.
        • Schreiber-Katz O.
        • Osmanovic A.
        • Petri S.
        • et al.
        Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study.
        Lancet Neurol. 2020; 19: 317-325
        • Walter M.C.
        • Wenninger S.
        • Thiele S.
        • Stauber J.
        • Hiebeler M.
        • Greckl E.
        • et al.
        Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3 – a prospective observational study.
        J Neuromuscul Dis. 2019; 6: 453-465
        • Mendonça R.H.
        • Polido G.J.
        • Matsui C.
        • Silva A.M.S.
        • Solla D.J.F.
        • Reed U.C.
        • et al.
        Real-world data from nusinersen treatment for patients with later-onset spinal muscular atrophy: a single center experience.
        J Neuromuscul Dis. 2021; 8: 101-108
        • Moshe-Lilie O.
        • Visser A.
        • Chahin N.
        • Ragole T.
        • Dimitrova D.
        • Karam C.
        Nusinersen in adult patients with spinal muscular atrophy: Observations from a single center.
        Neurology. 2020; 95: e413-e416
        • Veerapandiyan A.
        • Eichinger K.
        • Guntrum D.
        • Kwon J.
        • Baker L.
        • Collins E.
        • et al.
        Nusinersen for older patients with spinal muscular atrophy: A real-world clinical setting experience.
        Muscle Nerve. 2020; 61: 222-226
        • Pierzchlewicz K.
        • Kępa I.
        • Podogrodzki J.
        • Kotulska K.
        Spinal muscular atrophy: the use of functional motor scales in the era of disease-modifying treatment.
        Child Neurology Open. 2021; 8 (2329048X2110087)
        • Agosto C.
        • Salamon E.
        • Giacomelli L.
        • Papa S.
        • Benedetti F.
        • Benini F.
        Effect of the COVID-19 pandemic on children with SMA receiving nusinersen: what is missed and what is gained?.
        Front Neurol. 2021; 12704928
        • Farrar M.A.
        • Park S.B.
        • Vucic S.
        • Carey K.A.
        • Turner B.J.
        • Gillingwater T.H.
        • et al.
        Emerging therapies and challenges in spinal muscular atrophy.
        Ann Neurol. 2017; 81: 355-368
        • Finkel R.S.
        • McDermott M.P.
        • Kaufmann P.
        • Darras B.T.
        • Chung W.K.
        • Sproule D.M.
        • et al.
        Observational study of spinal muscular atrophy type I and implications for clinical trials.
        Neurology. 2014; 83: 810-817
        • Kanda Y.
        Investigation of the freely available easy-to-use software 'EZR' for medical statistics.
        Bone Marrow Transplant. 2013; 48: 452-458
        • Maggi L.
        • Bello L.
        • Bonanno S.
        • Govoni A.
        • Caponnetto C.
        • Passamano L.
        • et al.
        Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3.
        J Neurol Neurosurg Psychiatry. 2020; 91: 1166-1174